China's Lens Technology aims for July Hong Kong listing, sources say
HONG KONG, March 19 (Reuters) - Shenzhen-listed Chinese mobile screen maker Lens Technology (300433.SZ), opens new tab is planning to file an application for a Hong Kong listing by the end of this month, aiming to get the offering done in July, said two people with knowledge of the deal.
The company, which is one of the suppliers for Apple's (AAPL.O), opens new tab iPhone, has tapped CITIC Securities to sponsor the offering, the two people said, declining to be named as the information is confidential.
Bank of America has also been appointed to be the offering's overall coordinator, said one of them.
Lens Technology is aiming to raise $1 billion to $1.5 billion in the offering, the person said.
The company did not respond to a Reuters request for comment. CITIC Securities and Bank of America declined to comment.
The timing and terms of the offering is not set in stone and could change in line with market conditions, the people cautioned.
The Chinese protective panels producer for mobile phone displays said on March 12 it planned to issue H shares and to seek a listing on the Hong Kong bourse.
The company's shares have gained 18% this year. Lens Technology opened at 26.15 yuan ($3.62) a share on Wednesday, giving it a market cap of around $18 billion, LSEG data showed.
The shares were down nearly 1% on Wednesday afternoon at 25.89 yuan each.
($1 = 7.2330 Chinese yuan renminbi)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
21 minutes ago
- Reuters
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial
June 9 (Reuters) - Shares of weight-loss drug developer Metsera (MTSR.O), opens new tab gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a monthly dosing regime. The drug developer, which went public in January, is one of the many that are eyeing the lucrative market of weight-loss drugs that have been dominated by GLP-1 drugs from Novo Nordisk ( opens new tab and Eli Lilly (LLY.N), opens new tab. The drug, MET-233i, helped patients lose 8.4% of their weight, when adjusted for placebo, at 36 weeks. The drug belongs to a class of medicines which mimic the pancreatic hormone amylin that is co-secreted with insulin. It is being developed as a standalone treatment, and in combination with the company's other GLP-1 drug MET-097i. The two hormones combined suppress hunger, help control patients' blood glucose. Metsera's shares, which touched $35.19 in early trading, were up 5% at midday. The first wave of obesity drugs was based mainly on the gut hormone GLP-1, but drugmakers are looking for medicines that target other hormones or help preserve muscle while losing fat for their next generation of drugs. Data from Novo Nordisk's experimental drug CagriSema, which was touted to be the successor of its blockbuster obesity drug Wegovy, has so far fallen below investor expectations. Data from Metsera's 80-patient study showed that its drug has a half life of about 19 days, supporting once-a-month dosing. This compares to the five to seven days for Lilly's Zepbound and Novo's Wegovy that are taken weekly, said Evercore ISI analyst Umer Raffat. The so-called half life of a drug refers to the time it takes for the initial dose of the medicine to decrease by half in a patient's body. It helps determine how frequently a drug should be taken to achieve benefits. Drugmaker AstraZeneca (AZN.L), opens new tab is also testing an amylin-based obesity drug in early trials.
Western Telegraph
an hour ago
- Western Telegraph
Building materials firm Lords Group buys rival CMO in rescue deal
London-listed firm Lords said it acquired the 'trade and assets' of CMO for around £1.8 million as part of a pre-pack administration. The deal will secure the future of around 120 workers at Plymouth-based CMO, who will join the wider Lords group. CMO, which was founded in 2008 as Construction Materials Online, sells more than 140,000 products to trade professionals and households through a raft of specialist superstore-branded company was listed on London's AIM junior stock market until February, when it delisted in order to help preserve funds. The firms highlighted that the deal will not include the Tiles business previously owned by CMO. Dean Murray, chief executive of CMO, said: 'The acquisition marks a new and exciting chapter for CMO. 'We have built a strong, digitally-led business over the past 15 years, and in Lords, we have found a partner that not only understands our model but shares our ambition. 'I am incredibly proud of what the CMO team has achieved and excited about what is next.' Shanker Patel, chief executive of Lords, said: 'We are delighted to welcome CMO into the Lords family. 'CMO brings a well-established digital platform, strong customer reach, and a specialist product-led approach that complements our own. 'This partnership allows us to blend traditional merchanting strengths with cutting-edge digital capabilities. 'We are also mindful of the impact of the pre-pack administration process on affected parties and are committed to conducting the transition with respect.'
Reuters
2 hours ago
- Reuters
US wholesale inventories in April revised higher
WASHINGTON, June 9 (Reuters) - U.S. wholesale inventories increased in April amid stockpiling of prescription medication in anticipation of tariffs from the Trump administration. Stocks at wholesalers rose 0.2% instead of being unchanged, as estimated last month, the Commerce Department's Census Bureau said on Monday. Economists polled by Reuters had expected last month's estimate would be unrevised. Inventories, a key part of gross domestic product, climbed 0.3% in March. They advanced 2.3% on a year-over-year basis in April. Wholesale stocks of prescription medication surged 1.3% in April. There were also increases in apparel, motor vehicle, groceries and professional equipment inventories. President Donald Trump has said he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm to patients. Apart from drugmakers, businesses front-loaded imports in the first quarter, seeking to avoid Trump's sweeping duties on foreign goods, resulting in a large trade deficit that subtracted a record 4.90 percentage points from GDP. The front-running faded in April, leading to a record decline in imports and the overall trade deficit. While the contraction in the deficit at face value suggests trade could significantly add to gross domestic product in the second quarter, economists say some of the boost could be offset by low inventories. Inventory accumulation increased at a rate of $163.0 billion in the first quarter. The economy contracted at a 0.2% annualized rate in the January-March period, the first GDP decline in three years. It grew at a 2.4% pace in the fourth quarter. Sales at wholesalers edged up 0.1% in April after jumping 0.8% in March. At April's sales pace it would take wholesalers 1.30 months to clear shelves, unchanged from March.
